CD40 and CD40 Ligand in Immune-Mediated Vasculitis and Autoimmune Diseases: A Survey

Abstract

The CD40/CD40L interaction is a pivotal element in immune system regulation, significantly influencing immune responses and inflammation. This survey paper systematically examines the multifaceted roles of CD40 and CD40L, particularly in the context of immune-mediated vasculitis and autoimmune diseases. The CD40/CD40L axis is crucial for the activation of innate and adaptive immunity, enhancing antigen presentation, and promoting T cell proliferation. Dysregulation of this interaction contributes to the pathogenesis of autoimmune diseases such as rheumatoid arthritis and lupus vasculitis. The survey further explores the involvement of CD40/CD40L in platelet interactions, which are vital in inflammatory pathways. Therapeutic implications are discussed, highlighting current and emerging strategies targeting CD40/CD40L interactions, including antibody-based therapies, agonists, and combination therapies. The potential of serum soluble CD40 ligand (sCD40L) as a predictive biomarker is also examined. The survey concludes with a synthesis of key findings, emphasizing the translational potential of targeting the CD40/CD40L axis in treating inflammatory and autoimmune conditions. Future research directions are suggested to optimize therapeutic interventions and explore novel immunomodulatory strategies, enhancing our understanding of CD40/CD40L's role in immune regulation and its potential as a therapeutic target.

1 Introduction

1.1 Significance of CD40/CD40L in Immune-Mediated Diseases

The CD40-CD40L interaction is essential in the immune system, significantly influencing immune responses and inflammation. This interaction activates immune cells, including dendritic cells and T cells, enhancing their maturation and immunostimulatory functions. Activated platelets release CD40L, further promoting inflammation and immune responses, highlighting the complexity of the CD40-CD40L axis in immune regulation and its therapeutic potential in areas like cancer immunotherapy [1, 2]. This dyad is crucial for both innate and adaptive immunity, mediating the pathogenesis of immune-mediated diseases. CD40, found on antigen-presenting cells (APCs) and other cell types, engages with CD40L, primarily on activated T cells, to activate APCs and prime T cells, which is vital for effective immune surveillance and response.

In inflammation, the CD40/CD40L axis modulates the inflammatory environment, affecting immune cell behavior, particularly macrophages and T cells, central to the inflammatory response. The interaction between CD40L and platelets emphasizes the intricate relationship between immune cells and inflammation, significantly influencing inflammatory pathways. CD40/CD40L interactions promote T helper cell polarization towards a Th1 phenotype, characterized by pro-inflammatory cytokine production, such as IFN, exacerbating inflammatory conditions [2].

Dysregulation of CD40/CD40L signaling can lead to abnormal immune responses, contributing to autoimmune diseases like rheumatoid arthritis (RA) and lupus vasculitis (LV), a secondary vasculitis in systemic lupus erythematosus (SLE). In RA, CD40L overexpression plays a significant role in



Figure 1: chapter structure

disease pathology, marking it as a potential therapeutic target for modulating immune responses and enhancing treatment outcomes [3, 4, 5]. The differential expression of CD40 and its associations with other immune mediators across tumor types further underscore its relevance in anti-tumor immunity, suggesting therapeutic intervention targets.

The clinical application of serum soluble CD40 ligand (sCD40L) as a predictive biomarker illustrates the translational potential of the CD40/CD40L axis. For example, sCD40L may serve as a diagnostic tool for differentiating appendicitis types, potentially reducing the need for imaging methods that carry risks [6]. Understanding the CD40/CD40L axis is crucial in immune-mediated diseases, as these molecules are integral to the immune system's response to challenges and maintenance of homeostasis, representing promising targets for immunotherapy in treating inflammatory and autoimmune conditions effectively.

1.2 Structure of the Survey

This survey systematically examines the multifaceted roles of CD40 and CD40L in immune-mediated vasculitis and autoimmune diseases. It begins by establishing the significance of CD40/CD40L interactions in immune-mediated diseases, followed by an in-depth analysis of their roles in immune responses and inflammation. The introduction includes a discussion on the structure and function of CD40 and CD40L, elucidating their mechanisms in immune activation and the pathogenesis of vasculitis and autoimmune diseases.

The survey focuses on the CD40/CD40L signaling pathway's role in modulating immune responses and inflammation, emphasizing how this interaction facilitates immune cell communication and influences key inflammatory pathways, particularly in conditions like atherosclerosis and cancer [7, 8, 1, 9]. It further explores CD40/CD40L's role in platelet interactions, which are critical in inflammatory processes. Specific types of vasculitis and autoimmune diseases are examined, highlighting clinical manifestations and management challenges related to CD40/CD40L interactions.

Therapeutic implications are a significant component of the survey, discussing current and emerging strategies targeting CD40/CD40L interactions, including antibody-based therapies, agonists, combination therapies, and approaches targeting platelet functions in inflammatory diseases. The survey concludes with a synthesis of key findings, emphasizing the potential for therapeutic interventions

targeting CD40/CD40L and suggesting future research directions. Additionally, it briefly addresses related topics such as helminthic therapy and its mechanisms, which may provide insights into novel immunomodulatory strategies [10].The following sections are organized as shown in Figure 1.

2 Background and Core Concepts

2.1 CD40 and CD40L: Structure and Function

CD40, a 48 kDa type I transmembrane protein in the TNFR superfamily, is expressed on various hematopoietic and non-hematopoietic cells, notably APCs such as dendritic cells, B cells, and macrophages [11]. Its ligand, CD40L (CD154), primarily located on activated CD4+ T cells, B cells, and platelets, plays a crucial role in immune interactions. The CD40-CD40L interaction is essential for initiating and regulating immune responses, facilitating B cell proliferation, differentiation, and activation of macrophages and dendritic cells [7]. This interaction triggers intracellular signaling cascades vital for immune responses, recruiting TRAFs to CD40's cytoplasmic tail and activating pathways like NF-B, MAPK, and PI3K, which induce cytokine expression and enhance antigen presentation [12]. Recent studies highlight synaptic ectosomes' role in transferring CD40L, offering insights into its structural dynamics within the immune synapse [13].

CD40 signaling is crucial for immune activation and tolerance maintenance. Disruptions can lead to immunological disorders, including autoimmune diseases and immunodeficiencies. Therapeutically, modulating CD40 signaling has been explored to enhance immune responses against tumors. For example, CDX-1140, a human IgG2 antibody, has been developed to activate CD40 signaling in APCs, augmenting anti-tumor immunity [14]. These strategies underscore the dual role of CD40/CD40L interactions in promoting immune responses and serving as therapeutic targets in pathological conditions. The complexity and versatility of the CD40/CD40L dyad highlight its critical involvement in immune regulation and potential for therapeutic modulation in various immune-mediated diseases [7].

Additionally, soluble CD40L (sCD40L) impacts glomerular permeability, suggesting novel roles in conditions like focal segmental glomerulosclerosis (FSGS) [15]. Its ability to inhibit cell proliferation and promote apoptosis of cancer cells further underscores its significant function within the immune system [16]. Understanding these complex interactions is essential for developing effective therapeutic strategies targeting the CD40/CD40L pathway.

2.2 Mechanisms of CD40/CD40L in Immune Activation

The CD40/CD40L axis orchestrates immune activation through a sophisticated network of signaling pathways that underpin both innate and adaptive immunity. Upon CD40L engagement, CD40 recruits TRAFs, activating pathways such as NF-B, MAPK, and PI3K, essential for upregulating co-stimulatory molecules and cytokine production, thereby enhancing antigen presentation and T cell activation [17, 13, 18, 19]. Modulation of CD40 signaling is influenced by other receptors like Fas and TRAILR2, offering nuanced control over immune responses [20]. SE's role in the selective transfer of CD40L during immune synapse formation significantly impacts CD40/CD40L interactions, enhancing immune activation [13].

Beyond traditional immune pathways, sCD40L modulates cellular functions, inhibiting proliferation and promoting apoptosis of non-Hodgkin lymphoma (NHL) cells via the JNK signaling pathway, highlighting its therapeutic potential [16]. The interplay between CD40/CD40L and other immune mediators, such as CCL5, is crucial for shaping tumor immunity and the efficacy of CD40 agonist therapies [4]. Combining peptide vaccination with TLR agonists and IFA creates an immunogenic environment that enhances T-cell activation and promotes a Th1-dominant response, further potentiated by CD40/CD40L interactions [21]. This underscores the potential of leveraging CD40/CD40L pathways in designing effective immunotherapies and vaccines.

In rheumatoid arthritis, TNF blockade has been explored for its potential to inhibit CD154 expression, modulating CD40/CD40L interactions and reducing inflammatory responses [22]. The expression of CD40 in tumor cells is crucial for evaluating the efficacy of CD40-targeted therapies, emphasizing the importance of CD40/CD40L interactions in therapeutic contexts [23].

The complex mechanisms by which CD40/CD40L interactions activate immune responses highlight their essential function in immune regulation and promising potential as therapeutic targets in various medical conditions, including cancer immunotherapy and cardiovascular diseases. CD40 agonists have shown anti-tumor activity in advanced malignancies, while the CD40/CD40L dyad plays a critical role in modulating inflammation during atherosclerosis. The differential effects of membrane-bound versus soluble CD40L on immune cell activation underscore the multifaceted nature of CD40/CD40L signaling, suggesting the need for strategic therapeutic approaches leveraging these interactions to enhance immune responses in diverse clinical scenarios [2, 1, 24, 7, 5]. Understanding these mechanisms is essential for optimizing interventions aimed at modulating immune responses in various pathological conditions, including autoimmune diseases and cancer.

2.3 Pathogenesis of Vasculitis and Autoimmune Diseases

The pathogenesis of vasculitis and autoimmune diseases is intricately linked to dysregulated immune responses and chronic inflammation, with the CD40/CD40L axis playing a central role. Vasculitis, characterized by blood vessel inflammation, involves immune-mediated mechanisms leading to vessel wall damage and tissue ischemia. The interaction between immune cells and endothelial cells, facilitated by CD40/CD40L interactions, is crucial for initiating and perpetuating the inflammatory cascade defining vasculitis. Platelets actively participate in these processes, interacting with immune cells through the CD40L/CD40 axis to amplify inflammatory responses [1]. This interaction is further complicated in conditions like sepsis, where alterations in platelet production and phenotype can influence the inflammatory milieu [18].

Autoimmune diseases represent a complex group of disorders where the immune system fails to maintain tolerance, leading to inappropriate targeting of self-antigens. This breakdown in tolerance is influenced by genetic predispositions—often involving multiple genes regulating immune cell function—and environmental triggers, including infections and microbiota. Aberrant immune responses can manifest as autoantibody production, serving as crucial biomarkers for diagnosis and monitoring disease activity. The involvement of immune cells such as monocytes and macrophages plays a significant role in the inflammatory processes associated with these diseases, highlighting the intricate mechanisms underlying autoimmunity [10, 25, 26, 27]. Chronic inflammation in autoimmune conditions is compounded by the persistent presence of autoantibodies, exacerbating tissue damage and inflammation. The challenges in defining inflammation due to its complex and simultaneous molecular and physiological processes are particularly relevant to the pathogenesis of vasculitis and autoimmune diseases.

Mitochondrial dynamics, involving processes like fission and fusion, also influence immune cell behavior and function, potentially impacting the inflammatory environment in autoimmune diseases. Chronic inflammation and difficulty in eliminating senescent cells perpetuate a cycle of immune dysfunction, complicating the management of autoimmune conditions. The increased cardiovascular risk associated with chronic immune-mediated inflammatory diseases, such as rheumatoid arthritis and systemic lupus erythematosus, complicates clinical management strategies due to persistent inflammation contributing to atherosclerosis and other cardiovascular complications, necessitating the integration of anti-inflammatory approaches alongside traditional cardiovascular risk factor management [7, 28, 27].

In specific syndromes like X-linked hyper-IgM syndrome (X-HIGM), diagnostic complexities are heightened by atypical presentations, potentially leading to misdiagnosis. The deficiency of CD40 ligand in such conditions underscores the critical role of CD40/CD40L interactions in maintaining immune homeostasis and preventing autoimmunity. The diversity of the B cell receptor (BCR) repertoire is crucial in the pathogenesis of autoimmune diseases, influencing mechanisms such as autoantibody production and immune response activation, as well as affecting the efficacy of various treatment strategies, including the differential impacts of immunosuppressive therapies on B cell populations. Understanding the specific characteristics of the BCR repertoire in conditions like systemic lupus erythematosus and Crohn's disease may provide valuable insights into disease progression and potential therapeutic interventions [29, 30, 26].

The pathogenesis of cutaneous vasculitis, a subset of vasculitic disorders, is complicated by the lack of clear predictors and its relationship with systemic manifestations, complicating both diagnosis and management. The central role of innate immunity mediators in coordinating immune responses further emphasizes the complexity of these diseases. Understanding these intricate mechanisms is

essential for developing targeted therapies aimed at modulating the immune response and alleviating inflammation in vasculitis and autoimmune diseases. The use of biomarkers such as serum soluble CD40 ligand (sCD40L) in clinical settings exemplifies the translational potential of targeting the CD40/CD40L axis, as sCD40L levels have shown high sensitivity and specificity in predicting disease subtypes, such as in appendicitis [6].

3 CD40/CD40L in Immune Response and Inflammation

The CD40/CD40L axis is integral to immune cell interactions, significantly influencing immune responses and inflammation development. This section will analyze the mechanisms through which CD40/CD40L facilitates communication among immune cells, emphasizing its role in orchestrating immune responses and inflammation. Understanding these mechanisms is crucial for comprehending the functional significance of CD40/CD40L interactions in both normal and pathological contexts. Figure 2 illustrates the hierarchical structure of CD40/CD40L interactions, highlighting their roles in immune cell communication and inflammation. The top level categorizes the primary functions into immune cell interactions and platelet-related inflammatory pathways. The second level details specific mechanisms and modulatory effects, while the third level lists key processes and therapeutic insights, underscoring the axis's complexity and significance in immune responses.

3.1 Mechanisms of CD40/CD40L in Immune Cell Interactions

CD40/CD40L interactions are central to immune cell communication, contributing substantially to immune response orchestration and inflammation. This axis activates and regulates immune cells, including dendritic cells, B cells, and T cells. CD40 engagement on antigen-presenting cells (APCs) by CD40L on T cells activates APCs, enhancing antigen presentation and T cell stimulation. CDX-1140, a CD40 agonist antibody, exemplifies this by stimulating dendritic cells and B cells, thereby promoting T cell activation and a robust immune response [14].

Synaptic ectosomes at the immunological synapse facilitate CD40L transfer, crucial for effective immune responses [13]. These interactions are modulated by CD40's balance with other receptors like TRAILR2 and Fas, which can negatively regulate CD40 signaling, influencing immune responses in B cells [20]. The heteromerization of these receptors underscores the complexity of CD40-mediated signaling pathways and their impact on immune cell interactions.

Soluble CD40L (sCD40L) also modulates immune cell interactions. sCD40L can induce apoptosis in non-Hodgkin lymphoma (NHL) cells, highlighting its therapeutic potential and influence on immune cell dynamics [16]. The differential effects of membrane-bound CD40L (mCD40L) compared to sCD40L further illustrate nuanced immune response regulation, with mCD40L showing enhanced immunostimulatory effects [2].

Anti-CD40 antibodies enhance T cell activation and promote systemic immune responses, emphasizing the critical role of CD40/CD40L interactions in immune cell communication and immune response amplification [31]. Structural insights from studies on CD40 antagonists, such as ABBV-323, which stabilizes a non-signaling dimeric receptor form, provide a basis for understanding CD40 signaling modulation and its implications for immune regulation [11].

Figure 3 illustrates the mechanisms and therapeutic insights of CD40/CD40L interactions in immune cell communication. It categorizes the activation pathways, forms of CD40L, and therapeutic insights, highlighting key studies that contribute to understanding the immune response modulation and potential therapeutic applications. This figure provides a comprehensive overview of CD40/CD40L interactions' mechanisms in influencing immune cell behavior and inflammation. It includes a detailed depiction of CD40L and CD40 proteins' structural intricacies, highlighting crucial functional domains. A heatmap illustrates gene expression levels across two cell populations, shedding light on CD40/CD40L interactions' differential genetic activity. Western blot analysis of signaling proteins—ERK, JNK, and p38—in lymphoma cell lines Raji and CA46 provides empirical evidence of pathways activated during CD40/CD40L-mediated immune responses. These visual and analytical components underscore CD40/CD40L's multifaceted role in immune cell interactions and inflammation, making it a vital immunology study area [3, 9, 16].



Figure 2: This figure illustrates the hierarchical structure of CD40/CD40L interactions, highlighting their roles in immune cell communication and inflammation. The top level categorizes the primary functions into immune cell interactions and platelet-related inflammatory pathways. The second level details specific mechanisms and modulatory effects, while the third level lists key processes and therapeutic insights, underscoring the axis's complexity and significance in immune responses.

3.2 Platelet Interactions and Inflammatory Pathways

The CD40/CD40L axis is crucial in platelet interactions and their contribution to inflammatory pathways. Platelets, traditionally known for hemostasis, are now recognized as active immune response players. Upon activation, they express CD40L, interacting with CD40 on endothelial and immune cells, influencing inflammatory processes. This interaction is essential in vascular inflammation, facilitating leukocyte recruitment and activation, fostering an inflammatory environment exacerbating conditions like atherosclerosis and vasculitis. The CD40-CD40L pathway modulates immune cell interactions and the inflammatory response, critical in atherosclerosis progression and associated cardiovascular complications. Chronic inflammation in immune-mediated diseases contributes to



Figure 3: This figure illustrates the mechanisms and therapeutic insights of CD40/CD40L interactions in immune cell communication. It categorizes the activation pathways, forms of CD40L, and therapeutic insights, highlighting key studies that contribute to understanding the immune response modulation and potential therapeutic applications.

elevated cardiovascular risk by sustaining inflammatory processes exacerbating these conditions. Targeting this interaction may offer new therapeutic strategies to mitigate residual inflammatory risks in cardiovascular disease [7, 32, 28, 19].

Recent studies highlight splenic platelet production during sepsis, resulting in unique CD40L high platelets. These platelets enhance immune responses and reduce mortality in sepsis-challenged animals, underscoring CD40L expression's importance in modulating immune functions and improving inflammatory condition outcomes [18]. These platelets' interaction with CD40 on immune cells can potentiate inflammatory signaling pathways, including NF-B and MAPK, critical for pro-inflammatory cytokine and chemokine production.

Receptor heteromerization, as proposed in TNFRSF signaling, provides a framework for understanding CD40/CD40L interaction modulation. Receptor heteromerization may serve as a regulatory mechanism, impacting platelet-derived CD40L-mediated immune response strength and quality [20]. This regulatory capacity is particularly relevant in inflammatory diseases, where the balance between pro- and anti-inflammatory signals can influence disease progression and therapeutic outcomes.

4 CD40/CD40L in Vasculitis

4.1 Specific Types of Vasculitis Involving CD40/CD40L

CD40/CD40L interactions are crucial in the pathogenesis of vasculitis, influencing immune responses and inflammation. In cutaneous vasculitis, particularly in systemic lupus erythematosus (SLE) patients, these interactions exacerbate inflammation and organ damage, with a higher recurrence noted in African-American individuals, suggesting both racial and clinical predictors of disease progression [33]. In atherosclerosis, CD40L on T cells is vital for plaque formation and stability, contributing to vascular inflammation and cardiovascular risk [9]. CD40 ligand deficiency, predominantly seen in males from early life, suggests a genetic predisposition affecting vasculitic condition development [34]. This deficiency underscores the necessity of CD40/CD40L interactions for vascular integrity and immune response regulation.

Research into vasculitis underscores the significance of genetic predispositions and immune responses, alongside identifying novel biomarkers like soluble CD40 ligand (sCD40L). sCD40L's role as a permeability factor in focal segmental glomerulosclerosis (FSGS) highlights its impact on podocyte function and vascular inflammation [15]. CD40/CD40L interactions in vasculitic conditions are essential for orchestrating immune responses, particularly in atherosclerosis and cardiovascular diseases. Targeting the CD40/CD40L axis is a promising therapeutic strategy to mitigate inflammation and improve patient outcomes, as evidenced by recent studies on anti-CD40 and CD40L-targeting therapies [7, 1, 9, 3].

4.2 Clinical Manifestations and Challenges in Vasculitis Management

Vasculitis manifests in diverse clinical forms, reflecting the complex interplay between immune dysregulation and vascular inflammation. Lupus vasculitis affects about 50% of SLE patients, with symptoms ranging from mild cutaneous lesions to severe complications involving multiple organs [35, 33, 36]. The disease can impact various systems, causing skin rashes, renal impairment, neurological deficits, and systemic symptoms like fever and fatigue. CD40/CD40L interactions are critical, as they facilitate immune cell activation and inflammatory responses, leading to vascular damage. Specifically, CD40L expression on activated platelets and its interaction with CD40 on endothelial and immune cells are crucial for leukocyte recruitment, exacerbating vascular inflammation and tissue injury.

Managing vasculitis is challenging due to its heterogeneity, complicating diagnosis and treatment. The variability in clinical presentations necessitates a tailored diagnostic approach, involving clinical evaluation, laboratory tests, and imaging studies to confirm vasculitis and assess organ involvement. Soluble CD40 ligand (sCD40L) has emerged as a potential biomarker for disease monitoring and stratification, with elevated levels linked to increased disease activity across various conditions, including cancer and kidney disease. Notably, patients with neoplasia exhibit significantly higher serum sCD40L levels compared to healthy individuals, indicating its potential role in carcinogenesis. In chronic kidney disease, sCD40L levels correlate with renal function, underscoring its relevance in monitoring disease progression and therapeutic efficacy, highlighting its promise as a multifaceted biomarker in inflammatory and neoplastic diseases [7, 8, 24].

Therapeutically, vasculitis management typically involves immunosuppressive agents to control inflammation and prevent organ damage. However, the risks of adverse effects and relapse present significant challenges. Developing targeted therapies to modulate CD40/CD40L interactions offers a promising strategy for improving treatment outcomes. For instance, the novel role of the spleen in emergency platelet production introduces a new subset of platelets that may have therapeutic implications in sepsis and potentially in vasculitis, where platelet-mediated inflammation is a key feature [18].

5 CD40/CD40L in Autoimmune Diseases

The CD40/CD40L axis is pivotal in the pathogenesis of autoimmune diseases, influencing immune dysregulation, chronic inflammation, and tissue damage. This section explores specific autoimmune conditions, illustrating how CD40/CD40L interactions drive disease progression and inform therapeutic strategies.

5.1 CD40/CD40L in Specific Autoimmune Diseases

CD40 and CD40L are central to the pathophysiology of autoimmune diseases, mediating immune interactions that exacerbate disease. In systemic lupus erythematosus (SLE), primary Sjögren's syndrome (pSS), and rheumatoid arthritis (RA), CD40/CD40L signaling disrupts immune homeostasis, leading to chronic inflammation and tissue damage. CD40L, expressed by activated platelets and T cells, enhances dendritic cell activation and promotes pro-inflammatory mediator release, intensifying the inflammatory milieu [7, 1, 9].

In SLE, CD40/CD40L interactions are crucial for autoantibody production, a hallmark of the disease [29]. Aberrant B cell activation through CD40/CD40L signaling leads to pathogenic autoantibody generation, exacerbating inflammation and organ damage. In pSS, immune activation via CD40/CD40L is linked to exocrine gland impairment, though systemic therapies targeting this pathway have yet to show significant efficacy [37].

In RA, CD154 (CD40L) expression on T cells correlates with disease activity, with TNF blockade therapies showing promise in modulating CD40/CD40L interactions to improve outcomes [22]. This highlights the importance of CD40/CD40L in T cell-mediated inflammation within the synovial environment.

X-linked hyper-IgM syndrome (X-HIGM), caused by mutations in the CD40L gene, leads to impaired humoral and cellular immune responses. Patients exhibit decreased IgG and IgA levels, with normal or elevated IgM levels, increasing susceptibility to infections and autoimmune diseases. Some indi-

viduals may have milder symptoms due to hypomorphic mutations allowing partial CD40L function, as evidenced by a case of a 28-year-old man misdiagnosed with common variable immunodeficiency (CVID) until genetic testing confirmed X-HIGM [38, 34]. This condition highlights the critical role of CD40/CD40L in class-switch recombination and immune regulation.

Moreover, CD40/CD40L's role in T cell activation has implications in pancreatic cancer, where anti-CD40 therapies enhance systemic immune responses, suggesting potential applications in autoimmune-like inflammatory conditions [31]. These insights emphasize the dual role of CD40/CD40L in promoting immune activation and serving as a therapeutic target in autoimmune diseases, essential for developing novel strategies to modulate immune responses and alleviate autoimmune disease impacts.

5.2 Dual Role of CD40 in Autoimmune Responses

CD40 acts as a dual facilitator in immune responses, enhancing immune activation while contributing to autoimmune pathologies. This duality is evident in tumor immunotherapy, where CD40 activation boosts anti-tumor immunity, contrasting with its role in autoimmune diseases, where similar activation can worsen pathological responses [3]. The therapeutic potential of CD40 agonists in cancer is enhanced through combination therapies that optimize immune responses for a stronger anti-tumor effect [5].

In autoimmune conditions like pSS, CD40/CD40L interactions lead to aberrant immune responses, promoting lymphocyte activation and tissue injury [37]. This activation is complicated by chemokines such as CCL5, which selectively enhance CD4+ T cell infiltration, illustrating the intricate interplay between CD40 signaling and chemokine activity in immune regulation [39].

The role of CD40 in atherosclerosis exemplifies its dual nature; targeting CD40L functions in T cells can mitigate atherosclerotic inflammation while minimizing thrombotic risks associated with platelet CD40L [9]. Balancing these effects is crucial for developing therapeutic strategies that address the adverse consequences of CD40 activation in autoimmune contexts while preserving its beneficial immune defense roles.

Additionally, stochastic dynamics of T cell populations in autoimmune disease models suggest that CD40 signaling may contribute to the oscillatory behavior observed in autoimmune responses [40]. The modulation of immune responses by sex hormones, which can lead to sex-specific health outcomes, intersects with CD40 signaling pathways, adding complexity to its role in autoimmunity [41].

Therapeutic interventions, such as ABBV-323, aim to inhibit CD40-CD40L interactions without inducing agonist activity, thus minimizing potential side effects associated with immune activation [11]. This approach underscores the importance of selectively modulating CD40 signaling to achieve therapeutic benefits while reducing the risk of exacerbating autoimmune conditions. Understanding CD40's dual role in immune responses is vital for developing strategies that effectively balance its protective and pathogenic potentials in autoimmune diseases.

6 Therapeutic Implications and Strategies

6.1 Therapeutic Modulation of CD40/CD40L

Method Name	Therapeutic Strategies	Combination Therapies	Targeted Immune Modulation
sCD40L[16]	Scd40l Treatment	Agonistic Antibodies	Jnk Signaling Pathway
ABBV-323[11]	Antagonists And Agonists	-	Antagonist Monoclonal Antibodies
mCD40L[2]	Mcd40l Delivery	Exploring Combination Therapies	Precisely Controlling Immune

Table 1: Summary of therapeutic strategies and immune modulation methods involving CD40/CD40L interactions, highlighting the use of sCD40L, ABBV-323, and mCD40L. The table details the therapeutic approaches, combination therapies, and targeted immune modulation strategies associated with each method.

Modulating CD40/CD40L interactions presents a promising strategy for treating immune-mediated diseases by leveraging their roles in immune activation and inflammation. Quantitative assessments of CD40 expression enhance patient selection for clinical trials, optimizing therapeutic outcomes by

identifying those most likely to benefit from CD40-targeted interventions [23]. Agonistic anti-CD40 antibodies, combined with therapies like stereotactic body radiation therapy (SBRT), have shown potential in enhancing systemic immune activation and antitumor responses, indicating synergy in oncology [31]. Soluble CD40L (sCD40L) can activate apoptotic pathways in non-Hodgkin lymphoma (NHL) cells, suggesting its utility in targeted immune signaling modulation [16]. Table 1 summarizes the various therapeutic strategies and immune modulation methods being explored for CD40/CD40L interactions, emphasizing their potential applications in treating immune-mediated diseases.

The anti-CD40 monoclonal antibody ABBV-323, which acts as an antagonist by stabilizing the inactive dimeric form of the CD40 receptor, exemplifies innovative therapeutic strategies by minimizing adverse effects while achieving desired outcomes, particularly in autoimmune diseases requiring precise immune control [11]. Future research should focus on optimizing delivery methods for membrane-bound CD40L (mCD40L), exploring combination therapies, and assessing long-term immune responses, crucial for refining CD40/CD40L-targeted strategies [2].

Integrating diverse mechanisms, including CD40 agonists, helminth immunomodulation, and mitochondrial regulation, can develop innovative strategies to enhance both innate and adaptive immune responses. These approaches aim to improve outcomes in cancer and autoimmune diseases by addressing chronic inflammation, promoting effective immune surveillance, and optimizing treatment regimens [42, 10, 12, 17, 5].

6.2 Antibody-Based Therapies

Antibody-based therapies targeting CD40/CD40L interactions are emerging as promising strategies for modulating immune responses. Recent advancements in anti-CD40 antibodies demonstrate their potential to influence immune responses effectively across various therapeutic contexts, achieving progress with manageable side effects [3]. These therapies utilize CD40 agonists to stimulate robust antitumor immunity, supported by favorable safety profiles in early clinical trials [43]. ABBV-323 exemplifies their utility by preventing CD40L interaction, thereby avoiding subsequent immune activation [11].

Model-free control methods in immunotherapy have been employed to optimize CD40-targeted therapy administration, enhancing treatment precision and efficacy without extensive parameter identification [44]. Future research should validate the safety and efficacy of membrane-bound CD40L (mCD40L) in clinical trials, given its enhanced immunostimulatory properties compared to soluble CD40L (sCD40L). Elevated sCD40L levels may serve as biomarkers for differentiating between simple and complicated appendicitis, providing insights into inflammatory processes and broader implications of CD40/CD40L interactions [8, 6, 2]. Such studies are essential for expanding the therapeutic potential of antibody-based interventions targeting the CD40/CD40L axis, improving outcomes in cancer and autoimmune diseases.

6.3 Agonists and Combination Therapies

Agonists and combination therapies targeting CD40/CD40L pathways offer promising approaches for treating immune-mediated diseases. Agonistic anti-CD40 antibodies enhance immune responses by activating antigen-presenting cells and promoting robust T cell activation. These agonists are effective when combined with other therapeutic modalities, such as checkpoint inhibitors or chemotherapy, to achieve synergistic effects and improve clinical outcomes. Combining CD40 agonists with standard cancer therapies significantly enhances systemic immune activation, leveraging their ability to stimulate both innate and adaptive immune responses, as evidenced by their upregulation of costimulatory molecules and activation of CD8+ T cells. Clinical trials indicate that these agonists, especially when paired with immune checkpoint inhibitors or immunomodulatory treatments, amplify antitumor effects and induce favorable changes in the tumor microenvironment [3, 4, 43, 7, 5].

Identifying novel biomarkers to predict therapeutic responses to CD40-targeted therapies is crucial for tailoring treatment strategies to individual patients, optimizing efficacy while minimizing adverse effects. Well-designed clinical trials are essential for validating the safety and efficacy of combination therapies involving CD40 agonists, focusing on optimal dosing regimens and long-term outcomes [43]. Future research should explore the mechanistic underpinnings of CD40/CD40L interactions and their impact on immune regulation. Investigations into soluble CD40L (sCD40L) across various disease contexts, particularly in carcinogenesis and kidney disease, where elevated sCD40L levels

correlate with poorer outcomes, are warranted. Targeting sCD40L as a therapeutic strategy could leverage its proinflammatory properties and predictive role in neoplasia, enhancing immune responses and addressing renal injury [8, 24]. By deepening our understanding of these pathways, novel strategies can be developed to maximize the efficacy of CD40 agonists and combination therapies, improving patient outcomes in both cancer and autoimmune diseases.

6.4 Targeting Platelet Functions and Inflammatory Diseases

Modulating platelet functions via CD40L/CD40 interactions presents a promising therapeutic strategy for inflammatory diseases, given the integral roles of platelets in inflammation, immune responses, and vascular repair [7, 1, 32, 17]. Beyond hemostasis, platelets actively participate in immune responses and inflammation. CD40L expression on activated platelets facilitates interactions with CD40 on immune and endothelial cells, promoting leukocyte recruitment and inflammatory cascades, particularly in vascular inflammatory conditions like atherosclerosis and vasculitis.

Recent advancements in optimizing anti-CD40 antibodies aim to enhance therapeutic efficacy while minimizing adverse effects. Such optimization may involve designing antibodies that selectively engage Fc receptors or operate independently, balancing immune activation with safety considerations [3]. These strategies are crucial in inflammatory diseases, where precise immune response modulation is necessary to prevent exacerbation.

The discovery of a unique platelet population produced by splenic megakaryocytes during sepsis provides insights into platelet biology and therapeutic strategies. These platelets, characterized by high CD40L expression, enhance immune responses and improve outcomes in sepsis, suggesting potential utility in other inflammatory contexts [18]. Future research should elucidate the mechanisms by which splenic megakaryocytes influence platelet function and explore strategies leveraging this unique population to modulate inflammatory responses effectively.

To effectively target platelet functions in inflammatory diseases, a comprehensive approach is essential, recognizing the immunomodulatory roles of platelets and prioritizing the safety of therapeutic interventions amid the complex interplay of inflammation in conditions like atherosclerosis and aging [7, 1, 32, 17]. By advancing our understanding of platelet biology and optimizing antibody designs, novel strategies can be developed to harness the potential of platelet-targeted therapies in managing inflammatory diseases.

7 Conclusion

7.1 Challenges and Future Directions

The dualistic nature of CD40/CD40L interactions presents a significant challenge in therapeutic targeting, as they are integral to both immune activation and regulation. The potential to inadvertently amplify autoimmune responses necessitates the development of precise therapeutic strategies that can selectively modulate these interactions. Investigating the long-term effects of interventions such as TNF blockade and other mechanisms that influence T cell activation is crucial in conditions like rheumatoid arthritis. Additionally, understanding the role of soluble CD40L in podocyte function could lead to novel therapeutic approaches for diseases such as focal segmental glomerulosclerosis.

In oncology, optimizing CD40 agonist therapies and exploring novel combination strategies are essential for enhancing treatment efficacy and overcoming resistance. Further research should focus on validating CD40 expression across different disease stages and assessing its prognostic value. Large-scale clinical trials are needed to substantiate the effectiveness of CD40-targeted therapies in diverse disease contexts, including autoimmune conditions and cancer.

The intricate interplay of genetic and environmental factors in autoimmunity remains inadequately understood, highlighting the need for research aimed at developing effective diagnostic tools and innovative therapeutic strategies. This includes refining diagnostic criteria and exploring new treatment modalities for diseases like lupus vasculitis, which could significantly improve patient outcomes.

Enhancing our understanding of CD40/CD40L interactions and their role in immune regulation is pivotal for developing therapies that effectively balance immune activation and tolerance. Addressing these challenges and prioritizing future research directions can lead to improved therapeutic outcomes in both cancer and autoimmune diseases.

7.2 Emerging Trends and Future Directions

Recent advancements in the study of CD40 and CD40L have highlighted their complex roles in immune regulation, with emerging trends emphasizing the therapeutic potential of modulating these interactions. The development of CD40 agonists and antagonists is progressing, with research focusing on their applications in oncology and autoimmune diseases. These agents aim to leverage the immune-stimulatory properties of CD40/CD40L interactions while minimizing the risk of exacerbating autoimmune responses.

An important trend involves the exploration of combination therapies that integrate CD40-targeted treatments with other immunotherapeutic approaches, such as checkpoint inhibitors and TLR agonists, to enhance systemic immune activation and improve therapeutic outcomes. Additionally, the application of model-free control methods in optimizing CD40-targeted therapies shows promise in enhancing treatment precision and efficacy.

Future research should aim to elucidate the mechanistic intricacies of CD40/CD40L interactions, particularly their roles in immune cell communication and inflammatory response modulation. Investigating receptor heteromerization and selective engagement of CD40 signaling pathways could unveil novel therapeutic targets. Moreover, the potential of soluble CD40L as a biomarker for disease activity and therapeutic response merits further exploration, offering a non-invasive means of monitoring disease progression and treatment efficacy.

In autoimmune diseases, understanding the genetic and environmental factors influencing CD40/CD40L interactions is crucial for developing targeted interventions that address the root causes of these conditions. Research should focus on refining diagnostic criteria and exploring innovative therapeutic modalities, such as ABBV-323, which modulates CD40 signaling without inducing agonist activity.

The study of CD40/CD40L interactions continues to evolve, with emerging trends underscoring the importance of targeted therapies and combination strategies in optimizing immune modulation. By advancing our understanding of these interactions and pursuing innovative research directions, we can develop more effective treatments for both cancer and autoimmune diseases, ultimately improving patient outcomes.

References

[1] Fabrice Cognasse, Anne Claire Duchez, Estelle Audoux, Theo Ebermeyer, Charles Antoine Arthaud, Amelie Prier, Marie Ange Eyraud, Patrick Mismetti, Olivier Garraud, Laurent Bertoletti, et al. Platelets as key factors in inflammation: focus on cd40l/cd40. *Frontiers in immunology*, 13:825892, 2022.

[2] Taha Elmetwali, Asmaa Salman, Wenbin Wei, Syed A Hussain, Lawrence S Young, and Daniel H Palmer. Cd40l membrane retention enhances the immunostimulatory effects of cd40 ligation. *Scientific Reports*, 10(1):342, 2020.

[3] I Lang, O Zaitseva, and H FcγRs Wajant. Their relevance for the activity of anti-cd40 antibodies. *Int. J. Mol. Sci*.

[4] Dijana Djureinovic, Meina Wang, and Harriet M Kluger. Agonistic cd40 antibodies in cancer treatment. *Cancers*, 13(6):1302, 2021.

[5] Gregory L Beatty, Yan Li, and Kristen B Long. Cancer immunotherapy: activating innate and adaptive immunity through cd40 agonists. *Expert review of anticancer therapy*, 17(2):175–186, 2017.

[6] Serum soluble cd40 ligand in pre.

[7] Laura A Bosmans, Lena Bosch, Pascal JH Kusters, Esther Lutgens, and Tom TP Seijkens. The cd40-cd40l dyad as immunotherapeutic target in cardiovascular disease. *Journal of cardiovascular translational research*, 14:13–22, 2021.

[8] Anastasios Angelou, Efstathios Antoniou, Nikolaos Garmpis, Christos Damaskos, Stamatios Theocharis, and Georgios-Antonios Margonis. The role of soluble cd40l ligand in human carcinogenesis. *Anticancer Research*, 38(5):3199–3201, 2018.

[9] Michael Lacy, Christina Bürger, Annelie Shami, Maiwand Ahmadsei, Holger Winkels, Katrin Nitz, Claudia M van Tiel, Tom TP Seijkens, Pascal JH Kusters, Ela Karshovka, et al. Cell-specific and divergent roles of the cd40l-cd40 axis in atherosclerotic vascular disease. *Nature communications*, 12(1):3754, 2021.

[10] Taylor B Smallwood, Paul R Giacomin, Alex Loukas, Jason P Mulvenna, Richard J Clark, and John J Miles. Helminth immunomodulation in autoimmune disease. *Frontiers in immunology*, 8:453, 2017.

[11] Maria A Argiriadi, Lorenzo Benatuil, Ievgeniia Dubrovska, David A Egan, Lei Gao, Amy Greischar, Jennifer Hardman, John Harlan, Ramesh B Iyer, Russell A Judge, et al. Cd40/anti-cd40 antibody complexes which illustrate agonist and antagonist structural switches. *BMC molecular and cell biology*, 20:1–13, 2019.

[12] Anusha Angajala, Sangbin Lim, Joshua B Phillips, Jin-Hwan Kim, Clayton Yates, Zongbing You, and Ming Tan. Diverse roles of mitochondria in immune responses: novel insights into immuno-metabolism. *Frontiers in immunology*, 9:1605, 2018.

[13] Composition and structure of syn.

[14] Laura A Vitale, Lawrence J Thomas, Li-Zhen He, Thomas O'Neill, Jenifer Widger, Andrea Crocker, Karuna Sundarapandiyan, James R Storey, Eric M Forsberg, Jeffrey Weidlick, et al. Development of cdx-1140, an agonist cd40 antibody for cancer immunotherapy. *Cancer Immunology, Immunotherapy*, 68:233–245, 2019.

[15] Sophie Doublier, Cristina Zennaro, Luca Musante, Tiziana Spatola, Giovanni Candiano, Maurizio Bruschi, Luca Besso, Massimo Cedrino, Michele Carraro, Gian Marco Ghiggeri, et al. Soluble cd40 ligand directly alters glomerular permeability and may act as a circulating permeability factor in fsgs. *PLoS One*, 12(11):e0188045, 2017.

[16] Zhongxin Feng and Jishi Wang. Soluble cd40 ligand inhibits the growth of non-hodgkin's lymphoma cells through the jnk signaling pathway. *Oncology letters*, 21(1):56, 2021.

[17] Xia Li, Chentao Li, Wanying Zhang, Yanan Wang, Pengxu Qian, and He Huang. Inflammation and aging: signaling pathways and intervention therapies. *Signal transduction and targeted therapy*, 8(1):239, 2023.

[18] Colin Valet, Mélia Magnen, Longhui Qiu, Simon J Cleary, Kristin M Wang, Serena Ranucci, Elodie Grockowiak, Rafik Boudra, Catharina Conrad, Yurim Seo, et al. Sepsis promotes splenic production of a protective platelet pool with high cd40 ligand expression. *The Journal of clinical investigation*, 132(7), 2022.

[19] Paolo Tieri, Silvana Valensin, Vito Latora, Gastone C. Castellani, Massimo Marchiori, Daniel Remondini, and Claudio Franceschi. Quantifying the relevance of different mediators in the human immune cell network, 2004.

[20] Cristian R Smulski, Marion Decossas, Neila Chekkat, Julien Beyrath, Laure Willen, Gilles Guichard, Raquel Lorenzetti, Marta Rizzi, Hermann Eibel, Pascal Schneider, et al. Hetero-oligomerization between the tnf receptor superfamily members cd40, fas and trailr2 modulate cd40 signalling. *Cell death & disease*, 8(2):e2601–e2601, 2017.

[21] Karlyn E Pollack, Max O Meneveau, Marit M Melssen, Kevin T Lynch, Alexander F Koeppel, Samuel J Young, Stephen Turner, Pankaj Kumar, Katia Sol-Church, Ileana S Mauldin, et al. Incomplete freund's adjuvant reduces arginase and enhances th1 dominance, tlr signaling and cd40 ligand expression in the vaccine site microenvironment. *Journal for Immunotherapy of Cancer*, 8(1):e000544, 2020.

[22] Chien-Hsueh Tung, Ming-Chi Lu, Ning-Sheng Lai, and Shu-Fen Wu. Tumor necrosis factor-α blockade treatment decreased cd154 (cd40-ligand) expression in rheumatoid arthritis. *PLoS One*, 12(8):e0183726, 2017.

[23] Katherine M Bates, Ioannis Vathiotis, Tyler MacNeil, Fahad Shabbir Ahmed, Thazin Nwe Aung, Yuliya Katlinskaya, Sabyasachi Bhattacharya, Amanda Psyrri, Steven Yea, Amanda Parkes, et al. Spatial characterization and quantification of cd40 expression across cancer types. *BMC cancer*, 23(1):220, 2023.

[24] Shungang Zhang, Joshua D Breidenbach, Benjamin H Russell, Jerrin George, and Steven T Haller. Cd40/cd40l signaling as a promising therapeutic target for the treatment of renal disease. *Journal of Clinical Medicine*, 9(11):3653, 2020.

[25] Wen-Tao Ma, Fei Gao, Kui Gu, and De-Kun Chen. The role of monocytes and macrophages in autoimmune diseases: a comprehensive review. *Frontiers in immunology*, 10:1140, 2019.

[26] David S Pisetsky. Pathogenesis of autoimmune disease. *Nature Reviews Nephrology*, 19(8):509–524, 2023.

[27] Giuseppe Murdaca, Alessandro Tonacci, Simone Negrini, Monica Greco, Matteo Borro, Francesco Puppo, and Sebastiano Gangemi. Emerging role of vitamin d in autoimmune diseases: An update on evidence and therapeutic implications. *Autoimmunity reviews*, 18(9):102350, 2019.

[28] Jose Miguel Baena-Díez, Maria Garcia-Gil, Marc Comas-Cufí, Rafel Ramos, Daniel Prieto-Alhambra, Betlem Salvador-González, Roberto Elosua, Irene R Dégano, Judith Peñafiel, and María Grau. Association between chronic immune-mediated inflammatory diseases and cardiovascular risk. *Heart*, 104(2):119–126, 2018.

[29] RJM Bashford-Rogers, Laura Bergamaschi, EF McKinney, DC Pombal, Federica Mescia, JC Lee, DC Thomas, SM Flint, P Kellam, DRW Jayne, et al. Analysis of the b cell receptor repertoire in six immune-mediated diseases. *Nature*, 574(7776):122–126, 2019.

[30] Zhenke Wu, Livia Casciola-Rosen, Ami A. Shah, Antony Rosen, and Scott Zeger. Estimating autoantibody signatures to detect autoimmune disease patient subsets, 2017.

[31] Sayeda Yasmin-Karim, Patrick T Bruck, Michele Moreau, Sijumon Kunjachan, Gui Zhen Chen, Rajiv Kumar, Stephanie Grabow, Stephanie K Dougan, and Wilfred Ngwa. Radiation and local anti-cd40 generate an effective in situ vaccine in preclinical models of pancreatic cancer. *Frontiers in immunology*, 9:2030, 2018.

[32] Mihai G Netea, Frances Balkwill, Michel Chonchol, Fabio Cominelli, Marc Y Donath, Evangelos J Giamarellos-Bourboulis, Douglas Golenbock, Mark S Gresnigt, Michael T Heneka, Hal M Hoffman, et al. A guiding map for inflammation. *Nature immunology*, 18(8):826–831, 2017.

[33] Romy Kallas, Daniel Goldman, and Michelle A Petri. Cutaneous vasculitis in sle. *Lupus Science & Medicine*, 7(1):e000411, 2020.

[34] LFB Leite, TA Máximo, T Mosca, and Wilma Carvalho Neves Forte. Cd40 ligand deficiency. *Allergologia et Immunopathologia*, 48(4):409–413, 2020.

[35] Paul Brogan and Despina Eleftheriou. Vasculitis update: pathogenesis and biomarkers. *Pediatric Nephrology*, 33(2):187–198, 2018.

[36] Patrizia Leone, Marcella Prete, Eleonora Malerba, Antonella Bray, Nicola Susca, Giuseppe Ingravallo, and Vito Racanelli. Lupus vasculitis: an overview. *Biomedicines*, 9(11):1626, 2021.

[37] Benjamin A Fisher, Antonia Szanto, Wan-Fai Ng, Michele Bombardieri, Maximilian G Posch, Athena S Papas, Arwa M Farag, Thomas Daikeler, Bettina Bannert, Diego Kyburz, et al. Assessment of the anti-cd40 antibody iscalimab in patients with primary sjögren's syndrome: a multicentre, randomised, double-blind, placebo-controlled, proof-of-concept study. *The Lancet Rheumatology*, 2(3):e142–e152, 2020.

[38] Tábata T França, Luiz FB Leite, Tiago A Maximo, Christiane G Lambert, Nuria B Zurro, Wilma CN Forte, and Antonio Condino-Neto. A novel de novo mutation in the cd40 ligand gene in a patient with a mild x-linked hyper-igm phenotype initially diagnosed as cvid: new aspects of old diseases. *Frontiers in Pediatrics*, 6:130, 2018.

[39] Austin P Huffman, Jeffrey H Lin, Samuel I Kim, Katelyn T Byrne, and Robert H Vonderheide. Ccl5 mediates cd40-driven cd4+ t cell tumor infiltration and immunity. *JCI insight*, 5(10):e137263, 2020.

[40] F. Fatehi, S. N. Kyrychko, A. Ross, Y. N. Kyrychko, and K. B. Blyuss. Stochastic effects in autoimmune dynamics, 2018.

[41] Veena Taneja. Sex hormones determine immune response. *Frontiers in immunology*, 9:1931, 2018.

[42] Andrew J Rech, Hannah Dada, Jonathan J Kotzin, Jorge Henao-Mejia, Andy J Minn, Christina Twyman-Saint Victor, and Robert H Vonderheide. Radiotherapy and cd40 activation separately augment immunity to checkpoint blockade in cancer. *Cancer research*, 78(15):4282–4291, 2018.

[43] Da-Ke Li and Wen Wang. Characteristics and clinical trial results of agonistic anti-cd40 antibodies in the treatment of malignancies. *Oncology Letters*, 20(5):176, 2020.

[44] Ouassim Bara, Michel Fliess, Cédric Join, Judy Day, and Seddik M. Djouadi. Model-free immune therapy: A control approach to acute inflammation, 2016.

Disclaimer:

SurveyX is an AI-powered system designed to automate the generation of surveys. While it aims to produce high-quality, coherent, and comprehensive surveys with accurate citations, the final output is derived from the AI's synthesis of pre-processed materials, which may contain limitations or inaccuracies. As such, the generated content should not be used for academic publication or formal submissions and must be independently reviewed and verified. The developers of SurveyX do not assume responsibility for any errors or consequences arising from the use of the generated surveys.